26.9.2024 08:00:00 CEST | Thor Medical ASA | Non-regulatory press releases

Oslo, 26 September 2024: Thor Medical ASA, a leading emerging supplier of
alpha-emitters for next-generation precision cancer treatment, has today reached
mechanical completion of the Herøya pilot production facilities and initiated
commissioning.

"The construction of the pilot facilities has been completed on time and budget,
and with raw materials already in place at Herøya we are on track to begin
production in October and deliver the first product samples to customers before
the end of the year. This marks an important milestone as we move forward
towards commercial operations.", says Jasper Kurth, CEO of Thor Medical.

The pilot facilities will be used to verify production processes and product
quality and produce product samples for customer validation, and will also serve
as a platform for a scale-up to commercial production.

Thor Medical already has a concept study ongoing for the next phase of
commercial-scale production, with an investment decision expected by the end of
the first quarter 2025.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

 * Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
   brede.ellingseter@thormedical.no 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18254384/5032/Download%20announce
ment%20as%20PDF.pdf